ASX:BOTPharmaceuticals
A Look at Botanix Pharmaceuticals (ASX:BOT) Valuation Following South Korea ECCLOCK Gel Approval
Botanix Pharmaceuticals (ASX:BOT) is on the radar this week after its partner Dongwha Pharm secured a regulatory green light for ECCLOCK gel in South Korea, paving the way for a commercial launch in early 2026. This approval is not just another piece of good news for Botanix. It is a meaningful step in its push to grow outside Australia, with the company poised to collect a share of royalties from future sales. Investors tracking Botanix have been waiting for a sign that the company’s...